Media headlines about LivaNova (NASDAQ:LIVN) have been trending somewhat positive on Friday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. LivaNova earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.0408698571733 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of LivaNova (NASDAQ LIVN) opened at $80.82 on Friday. The stock has a market cap of $3,854.51, a PE ratio of 69.08, a PEG ratio of 2.20 and a beta of 0.61. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.03 and a quick ratio of 1.42. LivaNova has a 12 month low of $45.25 and a 12 month high of $88.56.
LivaNova (NASDAQ:LIVN) last issued its earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.76 by $0.17. The business had revenue of $309.70 million for the quarter, compared to analyst estimates of $301.22 million. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.78 EPS. sell-side analysts forecast that LivaNova will post 3.24 earnings per share for the current year.
A number of equities analysts have weighed in on the stock. Canaccord Genuity reissued a “hold” rating and issued a $71.00 price objective on shares of LivaNova in a research report on Wednesday, September 20th. ValuEngine cut shares of LivaNova from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. Zacks Investment Research cut shares of LivaNova from a “buy” rating to a “hold” rating in a research report on Thursday, December 21st. BidaskClub cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 12th. Finally, Needham & Company LLC upped their price objective on shares of LivaNova from $93.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. LivaNova currently has an average rating of “Hold” and a consensus price target of $79.71.
In other news, Director Hugh M. Morrison sold 1,830 shares of the company’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $88.00, for a total value of $161,040.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $74.58, for a total transaction of $74,580.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,830 shares of company stock worth $569,350. Company insiders own 0.28% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2018/01/05/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-livanova-livn-stock-price.html.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.